Search results for "SYNDROME CORONAVIRUS"

showing 10 items of 552 documents

First Report on the Latvian SARS-CoV-2 Isolate Genetic Diversity

2021

Remaining a major healthcare concern with nearly 29 million confirmed cases worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 920 thousand deaths since its outbreak in China, December 2019. First case of a person testing positive for SARS-CoV-2 infection within the territory of the Republic of Latvia was registered on 2nd of March 2020, 9 days prior to the pandemic declaration by WHO. Since then, more than 277,000 tests were carried out confirming a total of 1,464 cases of coronavirus disease 2019 (COVID-19) in the country as of 12th of September 2020. Rapidly reacting to the spread of the infection, an ongoing sequenci…

0301 basic medicineHCoV-19Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.disease_cause03 medical and health sciences0302 clinical medicinePandemicmedicineChinaOriginal ResearchCoronavirusGenetic diversitylcsh:R5-920SARS-CoV-2LatvianOutbreakCOVID-19General Medicinegenetic diversityVirologyLatvialanguage.human_language030104 developmental biologyGeography2019-nCoVlanguageMedicinenext-generation sequencingSevere acute respiratory syndrome coronaviruslcsh:Medicine (General)030217 neurology & neurosurgeryFrontiers in Medicine
researchProduct

Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities

2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand the effects of SARS-CoV-2 on the immune system, many mechanisms still remain unclear, hindering the development of novel therapeutic approaches and strategies to improve the host’s immune defense. This mini-review summarizes the findings on the role of γδ T cells in coronavirus disease 2019 (COVID-19), providing an overview of the excellent anti-viral therapeutic potential of γδ T cells, that had n…

0301 basic medicineImmune defense2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)virusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyGamma delta T cells03 medical and health sciences0302 clinical medicineImmune systemDrug DiscoveryMedicineCytotoxic T cellPharmacology (medical)PharmacologySARS-CoV-2business.industryRCOVID-19030104 developmental biologyInfectious Diseases030220 oncology & carcinogenesisPerspectiveImmunologyMedicinebusinessCD8Vaccines
researchProduct

Cutaneous manifestations associated with anosmia, ageusia and enteritis in SARS-CoV-2 infection - a possible pattern? Observational study and review …

2021

BACKGROUND: The cutaneous manifestations of coronavirus disease 2019 (COVID-19) have been covered insufficiently in the literature. METHODS: Thirty-nine patients admitted to the study hospital with confirmed COVID-19 who experienced various skin manifestations during hospitalization or in the convalescence period, were analysed retrospectively. RESULTS: Thirty-nine patients with COVID-19, admitted to the study hospital between 23 March and 12 September 2020, had intra-infectious rash or lesions of cutaneous vasculitis during convalescence. The most common cutaneous manifestations of COVID-19 were erythematous and erythematous papular rash. Twenty-seven of the 39 patients had anosmia (69.2%)…

0301 basic medicineMaleACE2 angiotensin‐converting enzyme 2ErythemaReceptor expressionTNF Tumor Necrosis Factor alphaInfectious and parasitic diseasesRC109-216B cells B lymphocyteslesions0302 clinical medicine030212 general & internal medicineskin and connective tissue diseasesCOVID coronavirus disease 2019media_commonEnterocolitisNK cells Natural killer cellsConvalescenceGeneral MedicineRashEnteritisInfectious DiseasesFemalemedicine.symptomCD Cluster of differentiationIHC immunohistochemistryMicrobiology (medical)medicine.medical_specialtyRT real-time reverse transcriptase–polymerase chain reactionmedia_common.quotation_subjectAnosmia030106 microbiologyAnosmiaSkin DiseasesArticle03 medical and health sciencesmedicineHumansbiopsySARS Severe acute respiratory syndrome coronavirus 2HE Hematoxylin and eosin stainRetrospective Studiescutaneous manifestationsbusiness.industrySARS-CoV-2SARS-CoV-2 infectionCOVID-19Ageusiamedicine.diseaseDermatologyPneumoniaIL 1 Interleukin 1IFN-γ Interferon γbusinessAgeusiaInternational Journal of Infectious Diseases
researchProduct

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

2020

Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers wer…

0301 basic medicineMaleAntibodies ViralSeverity of Illness IndexGastroenterologylaw.invention0302 clinical medicinelaw030212 general & internal medicinebiologyInflammatory biomarkersMiddle AgedIntensive care unitHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusFemaleAntibodyCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyPneumonia ViralNeutralizing antibodiesArticleVirus03 medical and health sciencesBetacoronavirusYoung AdultVirologyInternal medicineSeverity of illnessmedicineHumansPandemicsAgedRetrospective StudiesInflammationbusiness.industrySARS-CoV-2C-reactive proteinCOVID-19Retrospective cohort studyAntibodies NeutralizingFerritinbiology.proteinBinding Sites AntibodybusinessBiomarkers
researchProduct

Proper assignation of reactivation in a COVID-19 recurrence initially interpreted as a reinfection

2021

A 77-year-old-male (Case R) who had had a previous diagnosis of mild COVID-19 episode, was hospitalized 35 days later. On Day 23 post-admission, he developed a second COVID-19 episode, now severe, and finally died. Initially, Case R COVID-19 recurrence was interpreted as a reinfection due to the exposure to a SARS-CoV-2 RT-PCR-positive room-mate. However, whole-genome-sequencing indicated that case R recurrence corresponded to a reactivation of the strain involved in his first episode. Case R reactivation had major consequences, leading to a more severe episode, and causing a subsequent transmission to another two hospitalized patients, one of them with fatal outcome.

0301 basic medicineMalePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakFatal outcomeCoronavirus disease 2019 (COVID-19)Hospitalized patientsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies Viral03 medical and health sciences0302 clinical medicineNosocomial transmissionRecurrencemedicineImmunology and AllergyHumans030212 general & internal medicineAgedFirst episodeWhole Genome Sequencingbusiness.industrySARS-CoV-2Nosocomial transmissionBrief ReportCOVID-19Reactivation030104 developmental biologyInfectious DiseasesAcademicSubjects/MED00290ReinfectionbusinessWGS
researchProduct

Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemilu…

2021

medRxiv: https://doi.org/10.1101/2020.09.07.20188151

0301 basic medicineMalevirusesAntibodies ViralImmunoglobulin Glaw.invention0302 clinical medicineMedical microbiologylawMedicine030212 general & internal medicineNeutralizing antibodyImmunoassaychemistry.chemical_classificationmedicine.diagnostic_testbiologyAntibody titerGeneral MedicineMiddle AgedHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusOriginal ArticleFemaleAntibodyMicrobiology (medical)Adultmedicine.medical_specialtySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNeutralizing antibodiesSensitivity and SpecificityVirusCOVID-19 Serological Testing03 medical and health sciencesEnzyme-linked immunosorbent assayNeutralization TestsHumansAgedChemiluminescenceSARS-CoV-2business.industryfungiCOVID-19Antibodies NeutralizingVirologyChemiluminescent immunoassaysKineticsEnzymechemistryImmunoassayImmunoglobulin Gbiology.proteinbusiness
researchProduct

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine

2021

(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection

0301 basic medicineMedicine (General)Coronavirus disease 2019 (COVID-19)Chemiluminescence immunoassayvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryAsymptomaticArticleAntibodies03 medical and health sciencesR5-9200302 clinical medicineMedicineKineticMessenger RNAbiologySARS-CoV-2business.industryVaccinationvirus diseasesCOVID-19spikeVaccination030104 developmental biologyAntibody response030220 oncology & carcinogenesisImmunologybiology.proteinmedicine.symptomAntibodybusinessImmunosurvellianceVaccineS-RBD IgGDiagnostics
researchProduct

The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials

2021

Highlights • There is a need for reliable tools to predict the evolution of hospitalized patients suffering from COVID-19 • The likelihood of unfavourable evolution for patients hospitalized for COVID-19 with a National • Early Warning Score 2 (NEWS2) below 7 at Day 7 of hospitalization is nearly non-existent • Such a score could thus be used to allow earlier discharge of the patients and as a judgement criterion in therapeutic trials

0301 basic medicineMicrobiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNEWS2Communicable DiseasesArticle03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineUnfavourable eventAgedbusiness.industrySARS-CoV-2COVID-19Therapeutic trialCoronavirusHospitalizationInfectious DiseasesItalySARS-CoV2businessPredictionThe Journal of Infection
researchProduct

Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patien…

2021

Objectives There is limited information on the performance of rapid antigen detection (RAD) tests to identify SARS-CoV-2-infected asymptomatic individuals. In this field study, we evaluated the Panbio™ COVID-19 Ag Rapid Test Device (Abbott Diagnostics, Jena, Germany) for this purpose. Methods A total of 634 individuals (355 female; median age, 37 years; range, 9–87) were enrolled. Two nasopharyngeal swabs were collected from household (n = 338) and non-household contacts (n = 296) of COVID-19 cases. RAD testing was carried out at the point of care. The RT-PCR test used was the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, MA, USA). Results Household contacts were tested at a median …

0301 basic medicineMicrobiology (medical)AdultMale2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Rapid antigen detection testAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Point-of-Care Systems030106 microbiologyTest sensitivityImmunologic TestsAsymptomaticSensitivity and Specificity03 medical and health sciencesYoung Adult0302 clinical medicineCOVID-19 TestingInternal medicineMedicineHumans030212 general & internal medicineChildAntigens ViralAsymptomatic InfectionsAgedAged 80 and overImmunoassayFamily Characteristicsbusiness.industrySARS-CoV-2COVID-19General MedicineMiddle AgedTest (assessment)AsymptomaticResearch NoteInfectious DiseasesRapid antigen testCOVID-19 Nucleic Acid TestingClose contactsFemalemedicine.symptomContact TracingbusinessContact tracingClinical Microbiology and Infection
researchProduct

One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages.

2021

The COVID-19 pandemic was officially declared on March 11th, 2020. Since the very beginning, the spread of the virus has been tracked nearly in real-time by worldwide genome sequencing efforts. As of March 2021, more than 830,000 SARS-CoV-2 genomes have been uploaded in GISAID and this wealth of data allowed researchers to study the evolution of SARS-CoV-2 during this first pandemic year. In parallel, nomenclatures systems, often with poor consistency among each other, have been developed to designate emerging viral lineages. Despite general fears that the virus might mutate to become more virulent or transmissible, SARS-CoV-2 genetic diversity has remained relatively low during the first ~…

0301 basic medicineMicrobiology (medical)COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyReviewBiologyMicrobiologyGenomeVirusDNA sequencing03 medical and health sciencesVACCINESGenetic variationPandemicGeneticsHumansLineagesMolecular BiologyEcology Evolution Behavior and SystematicsTransmission (medicine)SARS-CoV-2VaccinationVariantsGenetic VariationCOVID-19Biological EvolutionVaccination030104 developmental biologyInfectious DiseasesEvolutionary biologyDiagnostic tests
researchProduct